The FMBA has completed a preclinical study of an antitumor drug

The Federal Medical and Biological Agency (FMBA) has completed preclinical studies of antitumor genetically engineered drug for cancer. This was announced on March 4 by Veronika Skvortsova, head of the agency, at the Women for a Healthy Society forum.

"For the treatment of the most severe, malignant, progressive, solid tumors resistant to traditional treatment methods, the FMBA Strategic Planning Center has created and successfully completed preclinical trials of an antitumor genetically engineered drug," she said in a video posted on the FMBA Telegram channel.

According to her, this drug carries two protoxin genes that are activated in tumor cells and trigger their death mechanisms. Skvortsova added that clinical trials will begin in 2025 as part of the new national project "Innovative Technologies for Health Savings."

Tread marks: there is a shortage of an unparalleled drug for cancer patients in the Russian Federation

How long will the mesna reserves last and when will the country have its own production?

Earlier, on February 26, oncologist of the highest qualification category, thoracic surgeon Andrey Nefedov spoke about the methods of detection href="https://iz.ru/1845231/2025-02-26/vrac-rasskazal-o-sposobah-vyavlenia-raka-legkogo-na-rannei-stadii " target="_blank">lung cancer at an early stage. For this, it is necessary to undergo a medical examination using low-dose computed tomography (NDKT) screening. They can detect small tumors in the lungs, which allows them to be removed in time and effective treatment can be carried out.